VENCLEXTA (venetoclax) has been approved by the Therapeutic Goods Administration (TGA) to treat patients with relapsed or refractory chronic lymphocytic leukaemia (CLL).
The first-in-class, once-daily oral B-cell lymphoma-2 inhibitor was discovered & developed as part of a joint research collaboration with the Walter and Eliza Hall Institute (WEHI) in Melbourne & AbbVie.
AbbVie said it was working with the Australian Government to make Venclexta available through PBS funding as early as possible.
In a Phase 2 clinical trial of Venclexta in 107 patients with previously treated CLL with 17p deletion, the overall response rate was 79%, the company said.
Visit tga.gov.au for details.
The above article was sent to subscribers in Pharmacy Daily's issue from 11 Jan 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 Jan 17
